Trials / Completed
CompletedNCT03631290
Deprescribing for Older Dialysis Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 48 (actual)
- Sponsor
- Duke University · Academic / Other
- Sex
- All
- Age
- 55 Years
- Healthy volunteers
- Not accepted
Summary
Aim 1 of the study is to identify the elements of a deprescribing intervention that address contextual factors specific to dialysis. Aim 2 of the study, described in this record, is to determine the feasibility of a deprescribing intervention tailored for older dialysis patients. Older adults receiving dialysis are often prescribed multiple medications. Some of these medications are used to treat symptoms, but they also can increase the chance of significant health problems. The purpose of this study is to identify if it is feasible to reduce the use of medications that have been identified as causing an increased risk for health problems.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Deprescribing Intervention | The deprescribing program was implemented as a clinical quality improvement project for patients receiving dialysis. Patients taking specific potentially inappropriate medications (PIMs) were identified in the medical record. The PIMs of interest included gabapentinoids, clonidine, alpha blockers, muscle relaxants, and Z-drugs. If their nephrologist agreed to attempt deprescribing the PIM, either the nephrologist (Provider Only Communication) or a study team member (pharmacist or nurse, Provider/Patient Communication) would engage the patient in discussion about deprescribing. This discussion included patient education materials about the risk of the medication. If the patient agreed, they were provided taper instructions (if indicated) and were followed up at 1 month and 3 months. The patient was also invited to enroll in a study to be interviewed about the deprescribing decision and experience, and undergo brief assessment of geriatric problems at baseline and at 3 months. |
Timeline
- Start date
- 2022-03-09
- Primary completion
- 2023-12-13
- Completion
- 2023-12-13
- First posted
- 2018-08-15
- Last updated
- 2025-02-03
- Results posted
- 2025-02-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03631290. Inclusion in this directory is not an endorsement.